21-Aug-2026
Ingevity’s Top Executive Makes a Major Insider Move
TipRanks (Tue, 18-Aug 10:12 PM ET)
Ingevity included in TIME America's Best Companies 2026 list
Business Wire (Tue, 18-Aug 9:00 AM ET)
Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact
Business Wire (Wed, 5-Aug 9:00 AM ET)
Ingevity reports second quarter 2026 financial results
Business Wire (Wed, 29-Jul 5:17 PM ET)
Ingevity's Evotherm P35 receives BASt approval in Germany
Business Wire (Thu, 16-Jul 12:49 PM ET)
Ingevity announces dates for second quarter 2026 earnings release and webcast
Business Wire (Thu, 2-Jul 6:00 AM ET)
John Fortson’s NGVT Tenure Highlights: Strategic Growth, Acquisitions, and Financial Discipline
Market Chameleon (Fri, 12-Jun 6:56 AM ET)
Dentsply Sirona Appoints John Fortson as Chief Financial Officer
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Business Wire (Tue, 9-Jun 5:21 PM ET)
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
Ingevity Common trades on the NYSE stock market under the symbol NGVT.
As of August 21, 2026, NGVT stock price climbed to $70.27 with 297,232 million shares trading.
NGVT has a beta of 0.52, meaning it tends to be less sensitive to market movements. NGVT has a correlation of 0.03 to the broad based SPY ETF.
NGVT has a market cap of $2.42 billion. This is considered a Mid Cap stock.
Last quarter Ingevity Common reported $314 million in Revenue and $1.74 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.40.
In the last 3 years, NGVT traded as high as $79.29 and as low as $28.49.
The top ETF exchange traded funds that NGVT belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
NGVT has outperformed the market in the last year with a return of +28.8%, while the SPY ETF gained +21.7%. In the last 3 month period, NGVT beat the market returning +7.8%, while SPY returned +3.4%. However, in the most recent 2 weeks NGVT has underperformed the stock market by returning -9.7%, while SPY returned -1.0%.
NGVT support price is $67.43 and resistance is $71.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NGVT shares will trade within this expected range on the day.